Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Image of human plasma in an IV bag

Plasma Biomarkers Predict Long-Term Kidney Function after Acute Kidney Injury

Plasma biomarkers may accurately identify patients with low risk for kidney function loss after acute kidney injury

National Kidney Foundation

Fueled by passion and urgency, National Kidney Foundation is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, NKF focuses on the whole patient through the lens of kidney health. Relentless in our work, we enhance lives through action, education and accelerating change.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Oct 13, 2021
|1 min read
Register for free to listen to this article
Listen with Speechify

Acute kidney injury (AKI), a sudden reduction in kidney function, often causes or worsens long-term kidney damage (called chronic kidney disease, CKD). This research evaluates a number of new blood tests (called biomarkers) in people who have had AKI, aiming to improve the ability to assess risk of new or progressive kidney disease. Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumour Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C, and eGFR. This combination discriminated between those with and without worsening CKD after three years and was particularly good at identifying those at lowest risk for progressive kidney disease. These findings published in the American Journal of Kidney Diseases (AJKD) suggest that biomarkers after AKI may be useful in identifying patients with very low risk of subsequent kidney dysfunction and a lower need for medical follow-up.

- This press release was provided by the National Kidney Foundation